The role of CD44 in cutaneous inflammation

Experimental Dermatology

Volumn 18, Issue 11, 2009, Pages 962-968

  Man, Mona ^a   Elias, Peter M ^a   Man, Wenyan ^a   Wu, Yan ^a   Bourguignon, Lilly Y W ^a,b   Feingold, Kenneth R ^a,b   Man, Mao Qiang ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Animal models; Barrier function; CD44; CD44 KO mice; Inflammation

Indexed keywords

HERMES ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; HYPERPLASIA; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IRRITANT DERMATITIS; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PROTEIN FUNCTION; SKIN ALLERGY; SKIN INFLAMMATION; SKIN PERMEABILITY;

ANIMALS; ANTIGENS, CD44; CYTOKINES; DERMATITIS, CONTACT; DISEASE MODELS, ANIMAL; EPIDERMIS; FEMALE; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HYPERPLASIA; INFLAMMATION; KERATINOCYTES; MICE; MICE, KNOCKOUT; SKIN;

EID: 70350759618     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00882.x     Document Type: Article

References (59)

1. Seiter S, Schmidt D S, Zoller M. The CD44 variant isoforms CD44v6 and CD44v7 are expressed by distinct leukocyte subpopulations and extent non-overlapping functional activities. Int Immunol 2000, 12:37-49.
2. Witting B, Seiter S, Schmidt D S, Zuber M, Zoller M. CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. Lab Invest 1999, 79:747-759.
3. Tuhkanen A L, Agren U M, Tammi M I, Tammi R H. CD44 Expression marks the onset of keratinocyte stratification and mesenchymal maturation into fibrous dermis in fetal human skin. J Histochem Cytochem 1999, 47:1617-1624.
4. Bourguignon L Y, Ramez M, Gilad E. Hyaluronan-CD44 interaction stimulates keratinocyte differentiation, lamellar body formation/secretion, and permeability barrier homeostasis. J Invest Dermatol 2006, 126:1356-1365.
5. Wang C, Tammi M, Tammi R. Distribution of hyaluronan and its CD44 receptor in the epithelia of human skin appendages. Histochemistry 1992, 98:105-112.
6. Seiter S, Schadendorf D, Tilgen W, Zoller M. CD44 variant isoform expression in a variety of skin-associate autoimmune diseases. Clin Immunol Immunopathol 1998, 89:79-93.
7. Kaya G, Rodriguez I, Jorcano J L, Vassalli P, Stamenkovic I. Selective suppression of CD44 in keratinocytes of mice bearing an antisense CE44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev 1997, 11:996-1007.
8. Kaya G, Tran C, Sorg O. Hyaluronate fragments reverse skin atrophy by a CD44-dependent mechanism. PLoS Med 2006, 3:2291-2303.
9. Kincade P W, He Q, Ishihara K, Miyaka K, Lesley J, Hyman R. CD44 and other cell interaction molecules contributing to B lymphopoiesis. Curr Top Microbiol Immunol 1993, 184:215-222.
10. Sugimoto K, Tsurumaki Y, Hoshi H. Effects of anti-CD44 monoclonal antibody on adhesion of erythroid leukemic cells (ELM-I-1) to hematopoietic supportive cells (MS-5): CD44, but not hyaluronate-mediated, cell-cell adhesion. Exp Hematol 1994, 22:488-494.
11. Funaro A, Spagnoli G C, Momo M, Knapp W, Malavasi F. Stimulation of T cells via CD44 requires leukocyte-function-associated antigen interactions and interleukin-2 production. Hum Immunol 1994, 40:267-278.
12. Huet S, Groux H, Caillou B, Valentin H, Prieur A M, Bernard A. CD44 contributes to T cell activation. J Immunol 1989, 143:798-801.
13. Foger N, Marhaba R, Zoller M. CD44 supports T cell proliferation and apoptosis by apposition of protein kinases. Eur J Immunol 2000, 30:2888-2899.
14. Zoller M, Gupta P, Marhaba R, Vitacolonna M, Freyschmidt-Paul P. Anti-CD44-mediated blockade of leukocyte migration in skin-associated immune diseases. J Leukoc Biol 2007, 82:57-71.
15. DeGrengele H C, Estess P, Siegelman M H. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997, 278:672-675.
16. Rothman B L, Blue M L, Kelley K A, Wunderlich D, Mierz D V, Aune T M. Human T cell activation by OKT3 is inhibited by a monoclonal antibody to CD44. J Immunol 1991, 147:2493-2499.
17. Pierres A, Lipcey C, Mawas C, Olive D. A unique CD44 monoclonal antibody identifies a new T cell activation pathway. Eur J Immunol 1992, 22:413-417.
18. Witting B, Seiter S, Foger N, Schwarzler C, Gunthert U, Zoller M. Functional activity of murine CD44 variant isoforms in allergic and delayed type hypersensitivity. Immunol Lett 1997, 57:217-223.
19. Seiter S, Engel P, Gohr N, Zoller M. Mitigation of delayed-type hypersensitivity reaction by a CD44 variant isoform v3-specific antibody: blockade of leukocyte egress. J Invest Dermatol 1999, 113:11-21.
20. Rosel M, Seiter S, Zoller M. CD44v10 expression in the mouse and functional activity in delayed type hypersensitivity. J Cell Physiol 1997, 171:305-317.
21. Camp R L, Scheynius A, Johansson C, Pure E. CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation. J Exp Med 1993, 178:497-507.
22. Gonda A, Gal I, Szanto S. CD44, but not I selectin, is critically involved in leukocyte migration into the skin in a murine model of allergic dermatitis. Exp Dermatol 2005, 14:700-708.
23. Sarraj B, Ludanyi K, Glant T T, Finnegan A, Mikecz K. Expression of CD44 and l-selectin in the innate immune system in required for severe joint inflammation in the proteoglycan-induced murine model of rheumatoid arthritis. J Immunol 2006, 177:1932-1940.
24. Stoop R, Kotani H, McNeish J D, Otterness I G, Mikecz K. Increased resistance to collagen-induced arthritis in CD44-deficient DBA/1 mice. Arthritis Rheum 2001, 44:2922-2931.
25. Verdrengh M, Holmdahl R, Tarkowski A. Administration of antibodies to hyaluronan receptor (CD44) delays the start and ameliorates the severity of collagen II arthritis. Scand J Immunol 1995, 42:353-358.
26. Mikecz K, Brennan F R, Kim J H, Glant T T. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat Med 1995, 1:558-563.
27. Nedvetzki S, Walmsley M, Alpert E, Williams R O, Feldmann M, Naor D. CD44 involvement in experimental collagen-induced arthritis (CIA). J Autoimmun 1999, 13:39-47.
28. Mikecz K, Dennis K, Shi M, Kim J H. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis. Arthrithis Rheum 1999, 42:659-668.
29. Farkas S, Hornung M, Sattler C. Short-term treatment with anti-CD44v7 antibody, but not VD44v4, restores the gut mucosa in established chronic dextran sulfate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 2005, 142:260-267.
30. Witting B, Schwarzler C, Fohr N, Gunthert U, Zoller M. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J Immunol 1998, 161:1069-1073.
31. Witting B M, Johansson B, Zoller M, Schwarzler C, Gunthert U. Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7). J Exp Med 2000, 191:2053-2064.
32. Liang J, Jiang D, Griffith J. CD44 is a negative regulator of acute pulmonary inflammatory and lipopolysaccharide-TLR signaling in mouse macrophages. J Immunol 2007, 178:2469-2475.
33. Man M Q, Shi Y, Man M. Chinese herbal medicine (Tuhuai extract) exhibits topical anti-proliferative and anti-inflammatory activity in murine disease models. Exp Dermatol 2008, 17:681-687.
34. Man M Q, Hatano Y, Lee S H. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 2008, 128:79-86.
35. Man M Q, Wood L, Elias P M, Feingold K R. Cutaneous barrier repair and pathophysiology following barrier disruption in IL-1 and TNF type I receptor deficient mice. Exp Dermatol 1999, 8:261-266.
36. Wood L C, Elias P M, Calhoun C, Tsai J C, Grunfeld C, Feingold K R. Barrier disruption stimulates interleukin-1 alpha expression and release from a pre-formed pool in murine epidermis. J Invest Dermatol 1996, 106:397-403.
37. Wood L C, Jackson S M, Elias P M, Grundfeld C, Feingold K R. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest 1992, 90:482-487.
38. Zhang R, Yang P Z, Wu C Y. Role of T-cell receptor V beta 8.3 peptide vaccine in the prevention of experimental autoimmune uveoretinitis. Chin Med J (Engl) 2006, 119:740-748.
39. Egwuagu C E, Mahdi R M, Nussenblatt R B, Gery I, Caspi R R. Evidence for selective accumulation of V beta 8+ T lymphocytes in experimental autoimmune uveoretinitis induced with two different retinal antigens. J Immunol 1993, 151:1627-1636.
40. Egwuagu C E, Bahmanyar S, Mahdi R M, Nussenblatt R B, Gery I, Caspi R R. Predominant usage of V beta 8.3 T cell receptor in a T cell line that induces experimental autoimmune uveoretinitis (EAU). Clin Immunol Immunopathol 1992, 65:152-160.
41. Teder P, Vandivier R W, Jiang D. Resolution of lung inflammation by CD44. Science 2002, 296:155-158.
42. Maytin E V, Chung H H, Seetharaman V M. Hyaluronan participates in the epidermal response to disruption of the permeability barrier in vivo. Am J Pathol 2004, 165:1331-1341.
43. Kulseth M A, Kolset S O, Ranheim T. Stimulation of serglycin and CD44 mRNA expression in endothelial cells exposed to TNF-alpha and IL-1alpha. Biochim Biophys Acta 1999, 1428:225-232.
44. van Grevenstein W M, Hofland L J, Jeekel J, van Eijck C H. The expression of adhesion molecules and the influence of inflammatory cytokines on the adhesion of human pancreatic carcinoma cells to mesothelial monolayers. Pancreas 2006, 32:396-402.
45. Mishra J P, Mishra S, Gee K, Kumar A. Differential involvement of calmodulin-dependent protein kinase II-activated AP-1 and c-Jun N-terminal kinase-activated EGR-1 signaling pathways in tumor necrosis factor-alpha and lipopolysaccharide-induced CD44 expression in human monocytic cells. J Biol Chem 2005, 280:26825-26837.
46. Gee K, Lim W, Ma W. Differential regulation of CD44 expression by lipopolysaccharide (LPS) and TNF-alpha in human monocytic cells: distinct involvement of c-Jun N-terminal kinase in LPS-induced CD44 expression. J Immunol 2002, 169:5660-5672.
47. Zoller M, Gupta P, Marhaba R, Vitacolonna M, Freyschmidt-Paul P. Anti-CD44-mediated blockade of leukocyte migration in skin-associated immune diseases. J Leukoc Biol 2007, 82:57-71.
48. Catalina M D, Estess P, Siegelman M H. Selective requirements for leukocyte adhesion molecules in models of acute and chronic cutaneous inflammation: participation of E- and P- but not L-selectin. Blood 1999, 93:580-589.
49. Schmits R, Filmus J, Gerwin N. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 1997, 90:2217-2233.
50. Stoop R, Gal I, Glant T T, McNeish J D, Mikecz K. Trafficking of CD44-defienct murine lymphocytes under normal and inflammatory conditions. Eur J Immunol 2002, 32:2532-2542.
51. Szanto S, Gal I, Glant T T, Mikecz K. Expression of L-selectin, but not CD44, is required for early extravasation in antigen-induced arthritis. J Immunol 2004, 172:6723-6734.
52. Fujita T, Fujimoto M, Matsushita T. Phase-dependent roles of E-selectin during chronic contact hypersensitivity responses. Am J Pathol 2007, 170:1649-1658.
53. Staite N D, Justen J M, Sly L M, Beaudet A L, Bullard D C. Inhibition of delayed-type contact hypersensitivity in mice deficient in both E-selectin and P-selectin. Blood 1996, 88:2973-2979.
54. Shimada Y, Hasegawa M, Kaburagi Y. l-selectin or ICAM-1deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. J Immunol 2003, 170:4325-4334.
55. Naor D, Nedvetzki S, Walmsley M. CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann N Y Acad Sci 2007, 1110:233-247.
56. Kim Y, Lee Y S, Hahn J H. Hyaluronic acid targets CD44 and inhibits FcepsilonRI signaling involving PKCdelta, Rac1, ROS, and MAPK to exert anti-allergic effect. Mol Immunol 2008, 45:2537-2547.
57. Hagemann I, Proksch E. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol 1996, 76:353-356.
58. Vazquez J R, Short B, Findlow A H. Outcomes of hyaluronan therapy in diabetic foot wounds. Diabetes Res Clin Pract 2003, 59:123-127.
59. Sobotka L, Smahelova A, Pastorova J, Kusalova M. A case report of the treatment of diabetic foot ulcers using a sodium hyaluronate and iodine complex. Int J Low Extrem Wounds 2007, 6:143-147.